Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques
- 12 February 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Cellular & Molecular Immunology
- Vol. 18 (4), 1058-1060
- https://doi.org/10.1038/s41423-021-00641-8
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivoScience, 2020
- Spike mutation D614G alters SARS-CoV-2 fitnessNature, 2020
- COVID-19 neutralizing antibodies predict disease severity and survivalPublished by Cold Spring Harbor Laboratory ,2020
- Large scale sequencing of SARS-CoV-2 genomes from one region allows detailed epidemiology and enables local outbreak managementPublished by Cold Spring Harbor Laboratory ,2020
- Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacyScience, 2020
- SARS-CoV-2 vaccines in developmentNature, 2020
- Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodiesCellular & Molecular Immunology, 2020
- Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 BindingCell, 2020
- A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoVScience, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020